Introduction
Osteoporosis is a worldwide disease characterized by reduction of bone mass and alteration of bone architecture resulting in increased bone fragility and increased fracture risk. ovarian failure, low body mass index, ethnic background (white persons are at higher risk than black persons), rheumatoid arthritis (RA), low BMD, vitamin D deficiency, low calcium intake, hyperkyphosis, current smoking, alcohol abuse, immobilization, and long-term use of certain medications, such as glucocorticoids, anticoagulants, anticonvulsants, aromatase inhibitors, cancer chemotherapeutic drugs, and gonadotropin-releasing hormone agonists.
2,4,13,14

Diagnosis
Osteoporosis is a silent disease without obvious symptoms and evidence until a fracture occurs. 5 Thus, screening by dual energy X-ray absorptiometry (DEXA) is important to obtain an early diagnosis and to avoid fractures. 5 All women aged 65 years or older and men aged 70 years or older, postmenopausal women with medical causes of bone loss (e.g., steroid use) regardless of age, postmenopausal women aged 50 years or older with additional risk factors for fracture (e.g., current smoker, RA, history of hip fracture in a parent), and postmenopausal women with a fragility fracture should be screened for osteoporosis by BMD measurement at the hip and lumbar spine as recommended by the U.S. Preventive Services Task Force (USPSTF), the National Osteoporosis Foundation, and by other guidelines.
10-12,15
BMD is mainly described as T-score, which represents the number of SD by which the BMD in an individual differs from the mean value expected in young healthy individuals.
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Based on the report of the WHO, BMD with a T-score above 1 SD is classified as normal BMD, a T-score between À1.0 and À2.5 SD is classified as osteopenia, and a T-score below À2.5 SD is defined as osteoporosis. 10 According to Gourlay et al, 16 rescreening intervals are 15 years for those with normal BMD (T-score ! À 1.0) or mild osteopenia (T-score < À 1.0 and > À 1.5), 5 years for those with moderate osteopenia (Tscore < À 1.5 and > À 2.0), and 1 year for those with advanced osteopenia (T-score < À 2.0 and > À 2.5).
Bone Turnover Biomarkers
Bone turnover biomarkers (BTMs) are produced from the bone remodeling process and can be measured in urine or serum. 
5,17
The total ALP concentration represents the sum of ALP isoenzymes from bones, liver, and intestine. In adults with normal liver function, almost 50% of ALP activity in serum is derived from bone and is produced by osteoblasts during bone formation. Therefore, measurement of total ALP activity lacks sensitivity and specificity in osteoporosis.
17 B-ALP is more specific for bone and, therefore, more sensitive in detecting the small changes in bone formation seen in osteoporosis. 17, 18 OC is considered a specific biomarker of osteoblast function for the evaluation of bone formation rate in osteoporosis. 5, 17 The concentration of P1NP and P1CP in serum reflects bone formation rate, 17 as they are produced during conversion of procollagen type 1 to collagen type 1.
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Kučukalić-Selimović et al 19 found that P1NP is significantly higher in postmenopausal females with osteoporosis compared with postmenopausal females with preserved bone mass, but its low specificity does not warrant its utility in diagnosing osteoporosis. HYP is produced from the degradation of bone collagen during bone resorption. 17 Since HYP can be found in other tissues such as skin and cartilage, it is considered a nonspecific marker of bone resorption. 5 Pyridinoline and DPD are released during breakdown of bone and cartilage; their concentration in urine are more sensitive and specific markers of bone resorption than urinary HYP. 17 TRAP 5b is normally secreted by osteoclasts and is considered a specific and high sensitive biomarker of bone resorption. 20 CTX-1
and NTX-1 are released during collagen degradation. CTX-1 is a specific and sensitive biomarker of bone resorption but is influenced by food intake, thus blood withdrawal must take place in the fasting state in the morning. 21 On the contrary, urinary NTX-1 is not affected by food intake.
17
According to the European guidance for the diagnosis and management of osteoporosis in postmenopausal women, the most informative ones for the investigation of osteoporosis are OC and P1NP for assessing bone formation and CT1X to assess bone resorption.
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According to the current guidelines on osteoporosis management, BTM cannot diagnose osteoporosis, but changes in BTMs may be useful in monitoring osteoporosis treatment to confirm the efficacy of treatment and treatment adherence.
11,21 Furthermore, the measurement of BTMs in women with a low BMD can improve the specificity of assessment of fracture risk.
21-24
Treatment
The primary goal of osteoporosis therapy is to reduce the risk of fracture. 25 Treatment and prevention strategies of osteoporosis and osteoporotic fractures include fall avoidance by correcting decreased visual acuity, reducing consumption of medication that alters alertness and balance, reducing fall hazards in the home (slippery floors, obstacles, insufficient light), practicing physical activity to improve muscle strength, balance, and maintaining bone mass, the avoidance of cigarette smoking and excessive alcohol intake, and adequate dietary intake of protein, calcium, and vitamin D. 11, 12, 26 In women, the recommended daily allowance observed that the risk of ONJ development is increased by several factors, such as duration of BP therapy, administration route of BP, type of BP, invasive dental procedures or dental prostheses, oncological disease, Caucasian origin, and multiple myeloma. Other adverse effects include hypocalcemia, influenza-like symptoms, uveitis, and episcleritis. 4 BPs are contraindicated in patients with low serum calcium and severe renal impairment (creatinine clearance below 30-35 mL).
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After 3 years of treatment with intravenous zoledronic acid or 5 years with oral BP, a treatment break should be considered as suggested by the American Society for Bone and Mineral Research, USPSTF, and the American College of Physicians (ACP), whereas if there are characteristics indicative of high fracture risk, such as old age, low hip T-score or high fracture risk score, previous major osteoporotic fractures, or fractures on therapy, it is recommended to continue the treatment with BPs up to 10 years.
4,11
Denosumab
Receptor activator of nuclear factor-kappa B ligand (RANKL) is expressed on the membrane of osteoblastic cells and binds to its receptor, RANK, on the surface of osteoclasts, which is essential for osteoclast formation, activity, and survival. Denosumab is a human monoclonal antibody that binds RANKL and prevents it from combining with RANK on the osteoclast membrane, thus inhibiting its action, favoring bone formation over bone resorption, and increasing bone mass and strength in both trabecular and cortical bone, thereby reducing radiographic vertebral, nonvertebral, and hip fractures in postmenopausal osteoporotic women.
4,31,32
Similarly to BP, denosumab therapy is associated with mild upper gastrointestinal symptoms, AFF and ONJ; moreover, it is associated with increased risk for infection, rash, and/or eczema. 4 Therefore, in patients considered at low risk of fracture after 5 years of treatment, discontinuation of denosumab is recommended, whereas in patients with a low BMD or multiple vertebral fractures or a high fracture risk score, it is advisable to continue treatment with denosumab for up to 10 years and consolidate with a single infusion of zoledronic acid.
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Strontium Ranelate
Strontium ranelate (Sr RAN) increases the osteoblast differentiation while osteoclast formation is inhibited simultaneously, thus Sr RAN significantly improves bone mass and quality, and increases bone strength; therefore, it remarkably reduces the risk of vertebral, nonvertebral, and hip fractures in a wide range of postmenopausal women with documented osteoporosis.
33
The most common reported adverse effects of Sr RAN are cardiovascular events, venous thromboembolism, myocardial infarction, gastrointestinal discomfort, and signs and symptoms of nervous system such as headache, seizure, and memory loss. 34 Sr RAN is not recommended for patients with severe renal impairment (creatinine clearance below 30 mL/min), patients with a previous history of thrombophlebitis, and patients with established current or previous history of ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease, and uncontrolled hypertension.
11,26
The Italian guidelines for the diagnosis, prevention, and management of osteoporosis stated that the use of Sr RAN must be restricted to the treatment of severe osteoporosis in postmenopausal women or in adult men with high risk of fracture for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible.
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Estrogen Replacement Therapy
Since menopause is characterized by estrogen deficiency that results in bone loss, it has been suggested that the use of ERT is effective for prevention of osteoporosis in postmenopausal women, but it is not recommended as the firstline preventive treatment of osteoporosis. 13 ERT is associated with an increased risk of coronary heart disease, breast cancer, stroke, and dementia. 
Selective Estrogen Receptor Modulator
Raloxifene is the only SERM widely available for the prevention and treatment of postmenopausal osteoporosis. 26 It reduces the risk of vertebral fractures in postmenopausal women with osteoporosis but has no effect on the risk for nonvertebral fractures. Therefore, it is not a first-line agent for postmenopausal osteoporosis. Moreover, the long-term use of raloxifene increases the risk of venous thromboembolic events.
2
ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. 4 
Calcitonin
Calcitonin inhibits osteoclastic bone resorption. 26 The use of a nasal spray formulation of salmon calcitonin to treat osteoporosis is associated with an increased risk of cancer. Hence, salmon calcitonin has been withdrawn from the market in Europe and Canada. Although it is available in the United States for treating osteoporosis (but not for prevention), the Food and Drug Administration Advisory Committee has not recommended it. 12,35 Drug-related adverse effects include nausea, local inflammation, and flushing of the face or hands when calcitonin is given as an injection, and local nasal irritation with the nasal spray formulation.
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Teriparatide
Teriparatide is a peptide corresponding to the 34 N-terminal amino acids of parathyroid hormone (PTH). Candidates for teriparatide treatment include patients with contraindications to oral and intravenous BPs, those who have had a major osteoporotic fracture while receiving oral BPs, and treatment-naive persons with very low BMD T-scores ( À 3.5).
2 It is contraindicated in conditions characterized by abnormally increased bone turnover (e.g., preexisting hypercalcemia, metabolic bone diseases other than primary osteoporosis, unexplained elevation of ALP, severe renal impairment, prior skeletal irradiation, or patients with skeletal malignancies or bone metastasis).
12,26
Teriparatide treatment reduces vertebral and nonvertebral fractures among women with postmenopausal osteoporosis. 4 Treatment with teriparatide is characterized by an early period dominated by bone formation that lasts for 6 to 9 months and is referred to as the anabolic window. Then, bone resorption increases and mitigates the overall bone anabolic effect.
36
Teriparatide treatment is associated with mild upper gastrointestinal symptoms, nausea, pain in the limbs, dizziness, headache, hypercalcemia, hypercalciuria, hyperuricemia, and hypotension. 4, 26 Moreover, the use of teriparatide is limited to 2 years in any life span, and this is because of the development of osteosarcoma in preclinical animal studies. 25 A study found that the addition of alendronate to teriparatide after the first 9 months of teriparatide treatment contributed to a reopening of the anabolic window and led to a return of bone resorption to levels comparable at the initiation of teriparatide therapy, whereas bone formation was less suppressed and remained elevated. 36 Furthermore, the recent denosumab and teriparatide administration study indicated that the combination of denosumab and teriparatide produced a more prominent effect on increasing BMD and decreasing fracture risk than each drug did alone. 38 It also indicated that teriparatide treatment after denosumab was associated with transient bone loss in lumbar spine and proximal femur and with prolonged BMD decrease in distal radius, while teriparatide followed by denosumab continuously increased the BMD of lumbar spine and proximal femur. The authors concluded that it is necessary to consider the timing of teriparatide use, as well as the order of sequential use of teriparatide, in the long-term management of patients with osteoporosis. 38 Finally, since discontinuation of estrogens, SERMs, denosumab, or teriparatide therapy is associated with a rapid loss of their effects on BMD and BTMs over 1 to 2 years, a follow-up treatment with BP should be considered to reduce or prevent the rebound increase in bone turnover.
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Conclusion
Osteoporosis is a skeletal disorder characterized by compromised bone strength leading to an increased risk of fracture.
It is defined as a BMD that lies 2.5 SD or more below the average value for young healthy women, as measured with DEXA. According to the current guidelines on osteoporosis management, BTMs cannot diagnose osteoporosis, but changes in BTMs may be useful in monitoring osteoporosis treatment to confirm the efficacy of treatment and treatment adherence and can improve the specificity of assessment of fracture risk. All postmenopausal women should be encouraged to maintain a healthy weight; to obtain adequate calcium, vitamin D, and protein intake; to participate in appropriate exercise; to avoid excessive alcohol consumption and smoking; and to utilize measures that prevent falls. Finally, drug therapy is recommended in all postmenopausal women who have a history of osteoporotic vertebral or hip fracture, in those who have BMD values consistent with osteoporosis, and in those who have T-scores from À1.0 to À2.5 and a 10-year risk of major osteoporotic fracture.
